Ingelheim Germany, May 17, 2013 - Professor Wolfram Carius, Member of the Board of Managing Directors of Boehringer Ingelheim GmbH, with responsibility for Biopharmaceuticals and Production, has decided to step down from the Board of Managing Directors of Boehringer Ingelheim GmbH effective 30 June 2013 and to leave the corporation. Prof. Carius has been with Boehringer Ingelheim for over 26 years and was on the Board of Managing Directors from 2009 for Human Resources and Operations, from 2012 for Biopharmaceuticals and Operations. Previously, he held various functions within the corporation in Development, Quality Control and Production. He was in charge of the production site in Brazil, played a significant part in the building up and expansion of Biopharmaceuticals and was a member of the Board of Managing Directors of Boehringer Ingelheim Germany. From 2005 to 2008, he was Corporate Division Head, responsible for Boehringer Ingelheim's worldwide pharma production network.
The Shareholders have appointed Dr Wolfgang Baiker as a new Member of the BMD. He will join the BMD on 1 June 2013 and from 1 July 2013 take over responsibility for Biopharmaceuticals and Production. The physician has been with the company since 1989 and has during this time held various functions in the Corporate Board Division Research, Development and Medicine in the USA and at the German sites in Biberach and Ingelheim (at Corporate Headquarters). In particular, he has also gained profound insights into the regulatory environment. From 2004 to 2009, he headed the group of the corporations' largest development site at Biberach. In addition, Dr Baiker took over the overall responsibility for Development worldwide in 2010.
Christian Boehringer, Chairman of the Shareholders' Committee and Prof Andreas Barner, Chairman of the Board of Managing Director of Boehringer Ingelheim stated: "On behalf of the Shareholders and the Board of Managing Directors, we would like to thank Prof. Carius for his thoroughly committed and very successful contribution to the company over many years. We are sad to see his departure and wish him all the best on his professional and personal way ahead.
Dr Baiker succeeds him as an experienced employee who has worked for the corporation for 24 years in different functions and who is especially familiar with the issues of Production as well as of Biopharmaceuticals, as he for years successfully accompanied the transition of products in development from Development to Production or Biopharmaceuticals. The Shareholders and the Board of Managing Directors are convinced that with this set up in the Board of Managing Directors, it will continue to be well-equipped for the diverse challenges that face Boehringer Ingelheim and the research-driven pharmaceutical industry worldwide".
The Boehringer Ingelheim group is one of the world's 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 140 affiliates and more than 46,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine.
Social responsibility is a central element of Boehringer Ingelheim's culture. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim's endeavors.
In 2012, Boehringer Ingelheim achieved net sales of about 14.7 billion euro. R&D expenditure in the business area Prescription Medicines corresponds to 22.5% of its net sales.